Novartis Stock Gets Weaker EPS Estimate from Zacks Research

Novartis AG (NYSE:NVS) – Equities research analysts at Zacks Research dropped their FY2028 EPS estimates for Novartis in a research report issued on Tuesday, November 10th. Zacks Research analyst Team now expects that the company will post earnings per share of $10.62 for the year, down from their previous forecast of $10.69. The consensus estimate for Novartis’ current full-year earnings is $9.08 per share.

Novartis (NYSE:NVS) last released its quarterly earnings data on Tuesday, October 27th. The company reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.25 by $0.21. Novartis had a net margin of 18.11% and a return on equity of 41.04%. The firm had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.53 billion. During the same quarter in the previous year, the firm earned $2.25 earnings per share. The firm’s revenue was up 4.4% on a year-over-year basis.

A number of other equities research analysts also recently issued reports on NVS. Sanford C. Bernstein reiterated a “neutral” rating on shares of Novartis in a research report on Wednesday, July 22nd. Wall Street Zen upgraded Novartis from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. DZ Bank assumed coverage on Novartis in a research note on Wednesday, October 28th. They issued a “hold” rating for the company. UBS Group reaffirmed a “neutral” rating on shares of Novartis in a report on Wednesday, October 28th. Finally, Deutsche Bank downgraded Novartis from a “hold” rating to a “sell” rating in a research report on Friday, October 30th. Six analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, Novartis presently has a consensus rating of “Hold” and a consensus target price of $152.25.

Novartis Trading Down 1.7%

Shares of Novartis stock opened at $160.41 on Thursday. Novartis has a 12-month low of $123.24 and a 12-month high of $170.46. The company has a current ratio of 0.88, a quick ratio of 0.70 and a debt-to-equity ratio of 0.98. The stock has a market cap of $306.08 billion, a PE ratio of 30.61, a price-to-earnings-growth ratio of 3.00 and a beta of 0.40. The company has a 50-day moving average of $149.23 and a two-hundred day moving average of $152.50.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of NVS. Highland Investment Advisors LLC acquired a new stake in shares of Novartis during the second quarter worth $25,000. Evolution Wealth Management Inc. increased its stake in Novartis by 552.0% in the second quarter. Evolution Wealth Management Inc. now owns 163 shares of the company’s stock valued at $26,000 after purchasing an additional 138 shares during the last quarter. Atlatl Advisers LLC acquired a new position in Novartis in the second quarter valued at $26,000. Archer Investment Corp increased its stake in Novartis by 93.0% in the first quarter. Archer Investment Corp now owns 166 shares of the company’s stock valued at $25,000 after purchasing an additional 80 shares during the last quarter. Finally, Silicon Valley Capital Partners lifted its position in Novartis by 519.4% during the second quarter. Silicon Valley Capital Partners now owns 192 shares of the company’s stock worth $30,000 after buying an additional 161 shares during the period. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Novartis News Roundup

These are some of the NVS news items that stood out recently:

• Positive Sentiment: Novartis reported continued benefits from ianalumab in a two-year study of Sjögren’s disease. Durable results could support the drug’s development prospects, though the reports do not provide detailed trial results here. Novartis’ Ianalumab Shows Continued Benefits In Two-Year Sjögren’s Study
• Neutral Sentiment: The estimate revisions were mixed: Zacks lowered forecasts for Q4 2026, Q1 2027, Q1 2028 and Q2 2028, while raising others. The changes are relatively small and do not indicate a broad downgrade to its annual outlook.
• Negative Sentiment: In particular, Zacks reduced its Q1 2028 EPS forecast to $2.45 from $2.54, and its Q2 2028 forecast to $2.70 from $2.72, tempering some of the positive revisions.

Novartis Company Profile

Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.